For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit: www.BMSStudyConnect.com
Inclusion Criteria:
- Qualify as having Systemic Lupus Erythematosus (SLE), according to the SLE
International Collaborating Clinics (SLICC) Classification Criteria ≥ 12 weeks before
the screening visit
- Test positive, as determined by the central laboratory, for at least one of the
following lupus related autoantibodies at the time of screening: antinuclear
antibody>/= 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or
anti-Smith antibody.
- Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or
rash
Exclusion Criteria:
- Active severe lupus nephritis (LN) as assessed by the investigator
- Neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI
- Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is
not SLE
- Antiphospholipid Syndrome
Other protocol-defined inclusion/exclusion criteria apply
